U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals: 1993-2016, Business and Industry Statistics


U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals: 1993-2016


* Beginning in 2004, these figures include new BLAs for therapeutic biologic products transferred from CBER to CDER.


Notes: The FDA defines a New Molecular Entity (NME) as a medication containing an active substance that has never before been approved for marketing in any form in the U.S.  Pharmaceutical R&D Spending includes expenditures inside and outside the U.S. by U.S.-owned PhRMA member companies and R&D conducted inside and outside the U.S. by the U.S. divisions of foreign-owned PhRMA member companies.  R&D performed by the foreign divisions of foreign-owned PhRMA member companies is excluded.




Source: Pharmaceutical Research and Manufacturers Association (PhRMA); U.S. Food and Drug Administration




A Representative List of Organizations that Have Used our Research and Products: